id: hepatitis_c_prevalence_to_kidney_disease
name: Hepatitis C Virus Infection â†’ Chronic Kidney Disease Progression
from_node:
  node_id: hepatitis_c_prevalence
  node_name: Hepatitis C Virus Infection
to_node:
  node_id: kidney_disease
  node_name: Chronic Kidney Disease Progression
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Hepatitis C virus (HCV) infection establishes chronic viral replication
  in the body, leading to systemic inflammation and immune complex formation'
- 'Step 2: HCV-associated immune complexes deposit in glomerular structures, causing
  HCV-associated glomerulonephritides (including membranoproliferative glomerulonephritis
  and cryoglobulinemic vasculitis)'
- 'Step 3: Beyond direct glomerular injury, HCV infection promotes systemic inflammation
  and metabolic dysregulation that accelerates kidney damage through mechanisms independent
  of glomerulonephritis'
- 'Step 4: The combination of direct glomerular injury and systemic effects leads
  to faster rates of GFR decline and CKD progression in HCV-infected individuals compared
  to uninfected patients'
- 'Step 5: Successful HCV treatment with direct-acting antivirals has been shown to
  slow the rate of GFR decline, supporting a causal relationship between HCV viremia
  and CKD progression'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: 'C. Gordon et al. 2019. Prevention, Diagnosis, Evaluation, and
    Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of
    the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline.
    Annals of Internal Medicine.'
  supporting_citations: []
description: Hepatitis C virus infection is an independent risk factor for faster
  rates of CKD progression. This relationship is mediated both through HCV-associated
  glomerulonephritides (including membranoproliferative glomerulonephritis and cryoglobulinemic
  vasculitis) and through mechanisms independent of direct glomerular disease. The
  KDIGO 2018 clinical practice guideline synthesis of 125 eligible studies supports
  this causal pathway, noting that successful HCV treatment with direct-acting antivirals
  results in slower GFR decline, providing evidence for reversibility of this effect.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: Successful HCV treatment
  direction: weakens
  strength: strong
  description: Direct-acting antivirals achieving viral eradication (>95% rate) result
    in slower GFR decline post-treatment compared to pre-treatment in patients with
    eGFR <60 mL/min/1.73 m2
- name: Dialysis modality
  direction: strengthens
  strength: moderate
  description: In-center hemodialysis patients have higher risk of nosocomial HCV
    transmission compared to peritoneal dialysis or home hemodialysis patients
- name: CKD stage
  direction: strengthens
  strength: moderate
  description: Higher CKD stages (lower GFR) combined with higher albuminuria categories
    increase risk classification and disease progression
